Activist DOMA Files Definitive Proxy, Seeks Board Control & Strategic Review Amid Patent Risks
PCRX sits 21% above its 52-week low of $18.8.
Summary
Activist investor DOMA Perpetual Capital Management has filed its definitive proxy statement, escalating its challenge to Pacira's board by nominating three directors and advocating for a strategic review, including a potential sale of the company.
Key Events · Corporate Governance and Compliance · PCRX
-
Proxy Contest Escalation
Activist DOMA Perpetual Capital Management (7.5% stake) filed its definitive proxy statement, intensifying its challenge to Pacira's board ahead of the June 9, 2026 annual meeting.
-
Board Nominees Proposed
DOMA is seeking to elect three independent director nominees to Pacira's Class III board, aiming to replace incumbent directors and drive a "strategic reset."
-
Call for Strategic Review & Potential Sale
The activist explicitly calls for the board to urgently evaluate strategic alternatives for EXPAREL, including a potential sale of the company, citing risks from generic competition and underperformance.
-
Opposition to Compensation & Dilution
DOMA recommends voting against executive compensation and against proposals to authorize an additional 3,000,000 shares for stock incentive and employee stock purchase plans, citing excessive dilution and misaligned incentives.
Analysis · PCRX · Life Sciences
This definitive proxy statement from activist investor DOMA Perpetual Capital Management intensifies the ongoing proxy contest, directly challenging Pacira's board and management. DOMA, holding a 7.5% stake, is pushing for the election of three new directors, a strategic review including a potential company sale, and votes against executive compensation and significant new share authorizations. The filing highlights critical concerns about the company's reliance on EXPAREL, the impact of generic competition, and perceived underperformance, suggesting a fundamental shift in governance and strategy is needed.
At the time of this filing, PCRX was trading at $22.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $898.4M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.